Denosumab treatment for osteoporosis raises the risk for hypocalcemia, which worsens with advancing stages of chronic kidney disease (CKD), in those with CKD–Mineral and Bone Disorder (CKD-MBD) and in ...
The researchers found that with denosumab vs oral bisphosphonates, the risk for emergently treated hypocalcemia increased with worsening CKD stage. (HealthDay News) — For patients with chronic kidney ...
The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...
Chronic kidney disease (CKD) has emerged as a global health challenge, largely due to its profound impact on mineral metabolism. Disruption of the tightly regulated balance of phosphate, calcium and ...
Findings showed treatment with Prolia significantly increased the risk of developing severe hypocalcemia compared with bisphosphonates, especially in patients with advanced CKD. In patients with ...
Colored x-ray of the pelvic region shows a fractured femur (red) caused by a fall. A lack of clinical trials and limited pharmaceutical options mean that management of this complication poses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results